EU-Wide OTC Approvals Highlight The Drawbacks Of National Processes
This article was originally published in The Tan Sheet
Executive Summary
National switches comprise the majority of OTC approvals in Europe, and likely will until the European Union opens restrictions on which drugs can use its nascent centralized switch process
You may also be interested in...
GSK Urges Regulatory Changes To Pull EU Market From Doldrums
The time appears right for Rx-to-OTC switches as European Union members struggle to control expanding health budgets in the face of aging populations and the continuing global economic crisis.
Centralized Switch Can Be Improved Via Practice, Practical Strategy
Over-the-counter drug makers can advance the EU centralized switch process by keeping the applications coming so that health authorities can "learn by doing," says Patrick Le Courtois, head of the human medicines development and evaluation unit at the European Medicines Agency
European Switch Progresses, But Stronger Incentives Needed For OTCs
Europe needs to provide more incentives for consumer firms, otherwise the OTC industry will "make commercial decisions" that could reduce their presence in the area, suggested Manfred Scheske, Glaxo-SmithKline's Consumer Healthcare Europe president and VP of the Association of the European Self-Medication Industry, speaking at that organization's meeting in London Jan. 20